NASDAQ:URGN
UroGen Pharma Ltd Stock News
$15.00
+0.0400 (+0.267%)
At Close: Mar 28, 2024
UroGen begins phase 3 trial of UGN-102 to treat bladder cancer
04:24pm, Thursday, 03'rd Feb 2022 Seeking Alpha
UroGen Pharma <> began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive
UroGen Pharma Ltd. (NASDAQ:URGN) Expected to Post Quarterly Sales of $17.20 Million
09:08pm, Wednesday, 22'nd Dec 2021 Dakota Financial News
Wall Street analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN) will announce sales of $17.20 million for the current quarter, Zacks reports. Two analysts have issued estimates for UroGen Pharmas earnings. The lowest sales estimate is $16.50 million and the highest is $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last []
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Bank of America Corp DE
09:28am, Sunday, 12'th Dec 2021 Dakota Financial News
Bank of America Corp DE grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 169.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,635 shares of the companys stock after buying an additional 56,313 shares during the period. Bank of America []
Jason Drew Smith Sells 3,803 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock
02:06pm, Saturday, 04'th Dec 2021 Dakota Financial News
UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Jason Drew Smith sold 3,803 shares of the firms stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total transaction of $45,750.09. The transaction was disclosed in a filing with the SEC, which is accessible through this link. []
UroGen pharma reports inducement grant to 13 new employees
04:37pm, Friday, 03'rd Dec 2021 Seeking AlphaUroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01:00pm, Friday, 03'rd Dec 2021 Kwhen FinanceUroGen Pharma Ltd. (NASDAQ:URGN) Expected to Announce Earnings of -$1.27 Per Share
09:08pm, Thursday, 02'nd Dec 2021 Transcript Daily
Wall Street brokerages predict that UroGen Pharma Ltd. (NASDAQ:URGN) will post earnings of ($1.27) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for UroGen Pharmas earnings, with estimates ranging from ($1.39) to ($1.08). UroGen Pharma reported earnings of ($1.38) per share during the same quarter last year, which []
UroGen Pharma Ltd. (NASDAQ:URGN) CFO Sells $31,121.61 in Stock
07:12pm, Thursday, 02'nd Dec 2021 Transcript Daily
UroGen Pharma Ltd. (NASDAQ:URGN) CFO Molly Henderson sold 2,587 shares of the companys stock in a transaction that occurred on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total value of $31,121.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []
Nuveen Asset Management LLC Cuts Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)
10:44am, Saturday, 27'th Nov 2021 Dakota Financial News
Nuveen Asset Management LLC decreased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 5.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 96,600 shares of the companys stock after selling 6,054 shares during the period. Nuveen Asset Management LLC owned approximately 0.46% of UroGen Pharma []
Zacks: Analysts Anticipate UroGen Pharma Ltd. (NASDAQ:URGN) Will Announce Quarterly Sales of $17.20 Million
07:30am, Saturday, 27'th Nov 2021 ETF Daily News
Wall Street analysts expect that UroGen Pharma Ltd. (NASDAQ:URGN) will announce $17.20 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for UroGen Pharmas earnings, with estimates ranging from $16.50 million to $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last year, which would [] The post Zacks: Analysts Anticipate UroGen Pharma Ltd. (NASDAQ:URGN) Will Announce Quarterly Sales of $17.20 Million appeared first on ETF Daily News .
UroGen Pharma (NASDAQ:URGN) Upgraded to Hold by Zacks Investment Research
12:00pm, Saturday, 20'th Nov 2021 Transcript Daily
Zacks Investment Research upgraded shares of UroGen Pharma (NASDAQ:URGN) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The companys product candidates include MitoGel and []
Urogen Pharma (URGN) Investor Presentation - Slideshow
06:58pm, Friday, 19'th Nov 2021 Seeking AlphaUroGen Pharma (NASDAQ:URGN) Issues Earnings Results, Misses Expectations By $0.09 EPS
01:30pm, Wednesday, 17'th Nov 2021 Dakota Financial News
UroGen Pharma (NASDAQ:URGN) released its earnings results on Monday. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.09), MarketWatch Earnings reports. UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. During the same quarter in the […]